Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.
By C. Klebanoff, L. Gattinoni, Parizad Torabi-Parizi, Keith W. Kerstann, A. Cardones, S. Finkelstein, D. Palmer, P. Antony, S. Hwang, S. Rosenberg and 2 more. Proceedings of the National Academy of Sciences of the United States of America, 2005
1,032 citations recorded by the source corpus.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/c48c26feba8cbefda8b88450da53acd375183906
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Oncology
Citations in the corpus
- L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity (2016, background): “…and favored the formation of Tcm-like cells that have been shown to be superior than effector memory T cells (Tem) in eradicating tumors in mouse models (Klebanoff et al., 2005), we reasoned that increased intracellular L-arginine levels might positively affect anti-tumor T cell responses in vivo.”
- Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo (2015, neutral): “…CD8 + T-cell clones derived from T CM but not T EM provided persistent immunity for more than four years 38,45 ; and TCR-Sommermeyer transgenic T-cells derived from the T N and T CM subsets conferred superior antitumor responses to melanoma than those derived from T EM37,46 .”
- Interleukin 12: still a promising candidate for tumor immunotherapy? (2014, background): “Central memory CD8 T cells have been demonstrated to exert stronger antitumor activity in tumor-bearing mice, as compared with effector memory CD8 T cells [100].”
- Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection. (2007, background): “A second situation that can dramatically alter memory CD8+ T cell differentiation is persisting infection (Klenerman and Hill, 2005; Wherry and Ahmed, 2004) (Figure 3 and Table 1).”
- Tumor-infiltrating lymphocytes in the immunotherapy era (2020, background): “Other studies around the same time highlighted the role of TCM cells in tumor control, as they possess high proliferative capacity and are suitable for adoptive T cell transfer, especially when combined with a tumor-antigen vaccination.(17) Accordingly, a recent study highlights the correlation of C”
- Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. (2014, background): “For long-term persistence, some adoptively transferred T cells must also enter secondary lymphoid organs and constantly replenish the pool of circulating T cells that then migrate to tumor sites.(13,28) The Figure 6.”
- Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. (2013, positive): “(46, 47) and chronic viral (48) models have demonstrated that CD8 + T cells with the capacity to home to secondary lymph nodes, where they can be effectively stimulated by professional antigen-presenting cells, are more effective in adoptive immunotherapy.”
- Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. (2008, background): “A prior study attempted to recapitulate in vivo programming of TCM and TEM by a single in vitro stimulation of naive tumor-specific CD8+ T cells from TCR-transgenic mice with antigen and either IL-2 to generate TEM or IL-15 to generate TCM (42).”
- Adoptive immunotherapy for cancer: harnessing the T cell response (2012, neutral): “Farelerde(122,123), insan olmayan primatlarda(124), hümanize edilmiş fare modellerinde(125) hafıza havuzunun içinde (memory pool) TCM hücreleri, TEM hücreleriyle karşılaştırıldığında artmış antitümör aktivite göstermiştir.”
- A human memory T-cell subset with stem cell-like properties (2011, background): “T cell proliferative and survival capacities correlate with the antitumor efficacy of adoptively transferred T cell”